CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B

EarningsYeztugoPositive
AI Analysis

Summary

Gilead's HIV prevention shot Yeztugo generated $232 million in Q2 sales, exceeding Wall Street estimates of $221 million. The HIV PrEP franchise has surpassed $1 billion in total sales.

Financial Highlights

Revenue

$232 million

Importance:6/10
Sentiment:
0.70
earningsbeatHIVPrEPfranchiseQ2 2026
Related Companies

Read the original article

Published by Endpoints News on August 5, 2026 1:21 AM

Read Original